Bin Suhail International
FOR IMMEDIATE RELEASE
Bin Suhail International to distribute Covid-19 tests
Abu Dhabi company to market test kits in UAE, Oman, and Saudi Arabia
Kuala Lumpur, Malaysia 5 January 2021
Bin Suhail International (Abu Dhabi) has been chosen by Universal Therapeutics Ltd. of Kuala Lumpur as sole distributor in United Arab Emirates, Oman, and Saudi Arabia for its licensed Beijing HotGen Biotech RNA PCR COVID-19 Nucleic Acid, and Beijing HotGen Biotech Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) test kits.
The appointment also grants Bin Suhail International the rights to distribute other Universal Therapeutics products, including its latex-free disposable Nitrile Butadiene Rubber examination gloves.
“The RNA PCR COVID-19 Nucleic Acid Test Kit is the gold standard for the detection of novel Coronavirus,” said Mr. Sidney Soares, Deputy Chief Executive Officer of Universal Therapeutics. “It detects Covid-19 through a one-step RT-PCR amplification process that identifies the virus in nasopharyngeal swabs, oropharyngeal swabs, and bronchoalveolar lavage fluids, and provides a result in approximately 120 minutes. The test is particularly effective for diagnosing the novel Coronavirus in suspected pneumonia patients, suspected clustering cases, and others requiring differential diagnosis.”
The Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) is ideal for rural or remote locations. It is easily administered, can be stored at room temperature, is more than 97 percent accurate, and provides results in just 15 minutes. The test detects the presence of viral proteins in acute or early Covid-19 infection by analysing secretion samples collected using nasal or throat swabs.
The powder-free, non-sterile nitrile examination gloves provide a full-textured, enhanced grip with strong puncture resistance. They are perfect for individuals who are allergic to natural rubber latex.
Bin Suhail International will begin accepting orders from customers in United Arab Emirates, Oman, and Saudi Arabia immediately.
To obtain brochures and summary data about the RNA PCR Test COVID-19 Nucleic Acid Test Kit (PCR-Fluorescent Probe Method) and the Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) rapid test kit, and other products, health care providers are urged to contact: groupsales@universal-therapeutics.com
Contact Details
About Universal Therapeutics:
Universal Therapeutics is a multinational pharmaceutical and biotech company based in Kuala Lumpur, Malaysia. The company’s businesses include manufacturing, distribution and white label production of pharmaceutical products, medical supplies, and PPEs in Asia and throughout the world.
Universal Therapeutics distribute nitrile gloves; three-ply face masks; KN95 and N95 masks; “HotGen Covid-19 RNA PCR” tests and “HotGen Novel Coronavirus 2019-nCoV Antigen (Colloidal Gold) – 15 Minutes Rapid” tests to wholesalers, medical institutions, and government organisations. Their products comply with World Health Organization (WHO) guidelines and are accredited and approved by various health ministries as safe for human use.
Subject to regulatory and safety approval, Universal Therapeutics has also been chosen to distribute Covid-19 vaccinations – in partnership with Beijing HotGen Biotech Co. Ltd. (688068:CH) – by China National Pharmaceutical Group Corporation (Sinopharm).
About Bin Suhail International:
Established in 1982, Bin Suhail International (BSI) is a UAE based local group with a rich diversity in business and delivering exceptional value for our customers and premium returns to stakeholders. We represent international groups in the local market and provide state of art service to ensure that their needs are met. Bin Suhail Group is committed to producing quality goods & services meeting customers specifications and following international standards while complying with local law.
For more information:
Samuel David Chai
Chief Commercial Officer
Office: +60 3 9213 0318
Email: GroupPR@Universal-Therapeutics.com
Website: www.Universal-Therapeutics.com